From these observations, it could also be speculated that highly specific inhibitors of ALK, PIM or Aurora-A/B (depending on the genetic characteristics and stage of the tumour) alongside metabolic inhibitors would markedly disrupt the progression of neuroblastomas whose aggressiveness is potentiated by the actions of these signalling pathways, particularly when in combination with MYCN-amplification. The gene discussed is PIM1; the disease is neoplasm.